Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
| Plasmid Name | Proper Citation | Insert Name | Organism | Bacterial Resistance | Defining Citation |
Comments |
||||
|---|---|---|---|---|---|---|---|---|---|---|
|
p663-UBC-miniTurbo-V5-PIK3C2G_IDG-K Resource Report Resource Website |
RRID:Addgene_170597 | miniTurbo-V5-PIK3C2G | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:10 | 0 | ||
|
pXL-BacII-CAG-mCherry Resource Report Resource Website |
RRID:Addgene_170519 | CAG-mCherry | Synthetic | Ampicillin | PMID:34458399 | More information can be found in this additional reference: Yamagata M, Yan W, Sanes JR. A cell atlas of the chick retina based on single-cell transcriptomics. Elife. 2021 Jan 4;10:e63907. doi: 10.7554/eLife.63907. PMID: 33393903; PMCID: PMC7837701. | Vector Backbone:pXL-BacII; Vector Types:Mammalian Expression, piggyBAC transposon; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:08 | 0 | |
|
pTR(EF)-tRNA(Q) Resource Report Resource Website |
RRID:Addgene_170517 | gRNAcore(EF)-tRNA(Q) | Drosophila melanogaster | Kanamycin | PMID:33782117 | For more information about the Han Lab Drosophila Transgenic Vectors, please visit: https://han.wicmb.cornell.edu/han-lab-drosophila-transgenic-vectors/ | Backbone Size:2352; Vector Backbone:pDONR221; Vector Types:PCR template vector for amplifying gRNAcore(EF)-tRNA(Q) fragment; used together with pAC-U63-tgRNA-nlsBFP or pAC-U63-tgRNA-Gal80; Bacterial Resistance:Kanamycin | 2026-08-15 01:10:09 | 0 | |
|
ZE19 wnt8 pBand3-5 Resource Report Resource Website |
RRID:Addgene_17053 | wnt8 pBand3-5 | Danio rerio | Ampicillin | PMID:11703928 | RT PCR prodct ligated into vector full length cDNA cloned includes ORF1, IRES and ORF2. For antiense RNA: transcribe with SP6 polymerase. Plasmid History: Species of Sequence Origin: Zebrafish. Reference: Lekven, Dev Cell, 2001. | Backbone Marker:Promega; Backbone Size:3000; Vector Backbone:pGemT easy; Vector Types:; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:08 | 0 | |
|
ZE7 Pax2 Resource Report Resource Website |
RRID:Addgene_17056 | pax b | Danio rerio | Ampicillin | PMID:7586754 | Insert: pax b sense or antisense orientation. Insert size: 1.18 Kb. Transcription: linearize at EcoR1, transcribe with SP6. Plasmid History: Constructed by Greg Kelly on date of 9/21/92, page 118 Book 1. Sepecies of Sequence Origin: Zebrafish. Note for Use: This construct is used to make DIG probes or for making RNA suitable for injections. Citation: Kelly and Moon, Developmental Genetics (1995) | Backbone Size:3000; Vector Backbone:SP64T; Vector Types:Zebrafish Expression; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | |
|
p663-UBC-miniTurbo-V5-MKNK2_IDG-K Resource Report Resource Website |
RRID:Addgene_170594 | miniTurbo-V5-MKNK2 | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:10 | 0 | ||
|
p663-UBC-miniTurbo-V5-EEF2K_IDG-K Resource Report Resource Website |
RRID:Addgene_170592 | miniTurbo-V5-EEF2K | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | ||
|
p663-UBC-miniTurbo-V5-MKNK1_IDG-K Resource Report Resource Website |
RRID:Addgene_170593 | miniTurbo-V5-MKNK1 | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | ||
|
p663-UBC-miniTurbo-V5-TP53RK_IDG-K Resource Report Resource Website |
RRID:Addgene_170589 | miniTurbo-V5-TP53RK | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:10 | 0 | ||
|
p663-UBC-miniTurbo-V5-TLK1_IDG-K Resource Report Resource Website |
RRID:Addgene_170588 | miniTurbo-V5-TLK1 | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | ||
|
pEPV-FLAG-DsRed2-ER-5 Resource Report Resource Website |
RRID:Addgene_170621 | EPV-FLAG-DsRed2-ER-5 | Synthetic | Kanamycin | PMID:35051356 | Please see the Genbank file under Resource Information for an annotated sequence file from the depositing laboratory. | Backbone Marker:Clontech; Backbone Size:4026; Vector Backbone:pDendra2-C; Vector Types:Mammalian Expression; Bacterial Resistance:Kanamycin | 2026-08-15 01:10:09 | 0 | |
|
p663-UBC-miniTurbo-V5-MARK3_IDG-K Resource Report Resource Website |
RRID:Addgene_170583 | miniTurbo-V5-MARK3 | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | ||
|
p663-UBC-miniTurbo-V5-PSKH1_IDG-K Resource Report Resource Website |
RRID:Addgene_170584 | miniTurbo-V5-PSKH1 | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | ||
|
p663-UBC-miniTurbo-V5-MAPK15_IDG-K Resource Report Resource Website |
RRID:Addgene_170581 | miniTurbo-V5-MAPK15 | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | ||
|
p663-UBC-miniTurbo-V5-LMTK2_IDG-K Resource Report Resource Website |
RRID:Addgene_170580 | miniTurbo-V5-LMTK2 | Homo sapiens | Ampicillin | These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community. These lentiviral gateway destination plasmids were generated, as part of the Kinase-Data and Resource Generating Center (DRGC), using the single fragment or multisite gateway cloning technology. They were used for generating proteomics-based protein-interaction and protein-proximity networks that can be accessed through the kinase-DRGC website https://darkkinome.org/. Each plasmid has either an N- or C-terminal fusion protein (Flag/ V5/V5-miniTurbo/V5-TurboID/miniTurbo-V5/TurboID-V5) tagged understudied kinase driven under either a CMV or Ubiquitin (UBC) promoter. All inserts in the pENTR plasmids used to generate the deposited destination plasmids were end-sequenced and insert size validated prior to multi-site gateway cloning. The combined insert size of the single fragment or three fragment destination plasmids were confirmed by restriction digestion (BsrGI, and EcoRV for pDest667; BsrGI, EcoRV, and BstZ17I for pDest663; and BsrGI for pHAGE) and all plasmids were partially sequenced to ensure in-frame ORFs and fusion tags. | Backbone Marker:PEL; Backbone Size:9019; Vector Backbone:pDest663; Vector Types:Mammalian Expression, Lentiviral, Gateway Destination; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | ||
|
pCAG-FLAG-puro-PTPIP51(1-150_175-470) Resource Report Resource Website |
RRID:Addgene_170537 | Protein tyrosine phosphatase interacting protein 51 | Homo sapiens | Ampicillin | PMID:33938112 | Note that deletion is of amino acids 151-175. | Backbone Size:6034; Vector Backbone:pCAG_FLAG_puro; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin | deleted amino acids 151-175 | 2026-08-15 01:10:09 | 0 |
|
pQlinkG2-PTPIP51(236-470) Resource Report Resource Website |
RRID:Addgene_170534 | Protein tyrosine phosphatase interacting protein 51 | Homo sapiens | Ampicillin | PMID:33938112 | Backbone Marker:Addgene; Backbone Size:5537; Vector Backbone:pQlinkG2; Vector Types:Bacterial Expression; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | ||
|
pQlinkH-PTPIP51(36-235) Resource Report Resource Website |
RRID:Addgene_170533 | Protein tyrosine phosphatase interacting protein 51 | Homo sapiens | Ampicillin | PMID:33938112 | Backbone Marker:Addgene; Backbone Size:4901; Vector Backbone:pQlinkH; Vector Types:Bacterial Expression; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:08 | 0 | ||
|
SPELL-ITSN1(DH-PH) Component 1 Resource Report Resource Website |
RRID:Addgene_170491 | mCherry, ITSN(N-lobe), iFKBP | Homo sapiens | Ampicillin | PMID:30279442 | The plasmid includes a 4 amino acid -GS linker (SGGS) downstream of mCherry that is not included in the original uploaded sequence. | Backbone Size:5000; Vector Backbone:pTriEx; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:09 | 0 | |
|
SITS-MmCav1-APEX2 Resource Report Resource Website 1+ mentions |
RRID:Addgene_170526 | Caveolin1 | Mus musculus | Ampicillin | PMID:33904409 | Vector Backbone:pCSDEST2 (Addgene 22424); Vector Types:leishmania cell free expression clone; Bacterial Resistance:Ampicillin | 2026-08-15 01:10:08 | 1 |
Can't find your Plasmid?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. If you want to find a specific plasmid, it's easier to enter an RRID or an Addgene Catalog Number to search. You can refine the search results using Facets on the left side of the search results page. If you are on the table view, you can also search in a specific column by clicking the column title and enter the keywords.
If you still could not find your plasmid in the search results, please help us by registering it into the system — it's easy. Register it with Addgene.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
